Clinical Trials Offer Patient Access to Groundbreaking Therapies
Investigational clinical trials are at the heart of innovation in brain tumor treatment.
At the Gerald J. Glasser Brain Tumor Center, we have a robust clinical trial research infrastructure in place. As a member of the National Cancer Institute (NCI) Cooperative Group System – and in partnership with several biotech/pharmaceutical companies and the Translational Genomics Research Institute, we offer patients access to groundbreaking, evolving therapies.
Currently, we are developing novel treatments for:
- Low-grade gliomas
- Glioblastoma
- Other high-grade primary brain tumors
- Metastatic brain tumors
- Tumors that cause malignant cells to spread to the fluid surrounding the brain and spinal cord.
To treat these challenging tumors, we are focusing on immunotherapies, CAR-T strategies, oncolytic tumor viruses and other targeted therapies.
If you’re interested in learning more about specific clinical trials that are underway and enrollment, please contact 908-522-5768.
NEW CLINICAL TRIAL
NRG-BN007 (MGMT-Unmethylated Glioblastoma): Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma
ENROLLING NOW